Localization and characterization of human papillomavirus-16 in oral squamous cell carcinoma

Oral Dis. 2023 Mar;29(2):436-444. doi: 10.1111/odi.13920. Epub 2021 Jun 21.

Abstract

Objectives: The role of Human papillomavirus (HPV) in the oral squamous cell carcinoma (OSCC) has not been completely elucidated. The purpose of the present study was to investigate the prevalence and localization of HPV-16 virus in OSCC and to correlate HPV-16 positivity and p16INK4A expression with the clinical and pathological features of OSCC.

Methods: The archives of Oral Pathology at the University of Florida, College of Dentistry were accessed for demographic, clinical, histopathological data, and slides of 114 OSCC patients. HPV-16 positivity of OSCC was evaluated by p16INK4A immunohistochemistry (IHC) and HPV-16 E6/E7mRNA by in situ hybridization (ISH).

Results: Out of 114 consecutive pathological slides of OSCC, 16 samples (14%) showed positivity for p16INK4A by IHC and 14 samples (12%) were positive for HPV-16 E6/E7mRNA ISH and the Positivity showed a significant correlation with the patients' age, alcohol consumption, and the degree of OSSC differentiation. The hard palate showed the highest positivity of p16INK4A IHC and HPV-16 mRNA ISH (38%, 36% respectively).

Conclusion: HPV-16 is a significant factor in oral carcinogenesis. We recommend using p16INK4A as a surrogate marker for HPV detection in OSCC, which can be complemented by RNA ISH for the identification of HPV subtypes.

Keywords: human papillomavirus; immunohistochemistry; in situ hybridization; oral squamous cell carcinoma; p16INK4A.

MeSH terms

  • Carcinoma, Squamous Cell* / pathology
  • Cyclin-Dependent Kinase Inhibitor p16 / metabolism
  • Head and Neck Neoplasms*
  • Human Papillomavirus Viruses
  • Human papillomavirus 16 / genetics
  • Humans
  • Mouth Neoplasms* / pathology
  • Papillomaviridae / genetics
  • Papillomavirus Infections* / complications
  • Papillomavirus Infections* / diagnosis
  • Squamous Cell Carcinoma of Head and Neck

Substances

  • Cyclin-Dependent Kinase Inhibitor p16